Most randomized trials of insulins include very few older individuals, a population that is heterogeneous with respect to prevalence and severity of comorbidity, frailty and overall health.22 Consequently, little information exists concerning the performance of basal insulin analogues in older individuals with diabetes, particularly with respect to hypoglycaemia. The gene discussed is INS; the disease is diabetes mellitus.